Comparison of Standard of Care or Treatment on Protocol
NCT01010334 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13
Last updated 2013-08-14
Summary
Patient will choose to either receive the standard of care according to National Comprehensive Cancer Network (NCCN) or approved guidelines for their condition or to be treated according to one arm of the protocol that they could not be enrolled on. The selection of the arm will be at physician discretion.
Conditions
- Stomach Cancer
- Esophageal Cancer
- Bladder Cancer
- Skin Cancer
- Lung Cancer
- Uterine Cancer
- Ovarian Cancer
Interventions
- OTHER
-
standard of care
All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
Sponsors & Collaborators
-
New Mexico Cancer Research Alliance
lead OTHER
Principal Investigators
-
Claire Verschraegen, MD · University of New Mexico Cancer Center
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-03-31
- Primary Completion
- 2011-07-31
- Completion
- 2011-07-31
Countries
- United States
Study Locations
More Related Trials
-
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
NCT04485026 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
NCT00614484 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
NCT00161278 ·Status: TERMINATED ·Phase: PHASE2
-
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
NCT00168896 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
NCT06375109 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
NCT06585189 ·Status: COMPLETED
-
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
NCT04696939 ·Status: UNKNOWN ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
NCT03348748 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996 ·Status: RECRUITING ·Phase: PHASE3
-
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01711697 ·Status: UNKNOWN ·Phase: PHASE1
-
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00003240 ·Status: UNKNOWN ·Phase: PHASE3
-
Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
NCT00683904 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
NCT01702714 ·Status: WITHDRAWN ·Phase: PHASE1
-
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00682383 ·Status: COMPLETED ·Phase: PHASE2
-
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
NCT06800339 ·Status: RECRUITING ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
NCT04631029 ·Status: COMPLETED ·Phase: PHASE1
-
Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
NCT01038661 ·Status: COMPLETED ·Phase: PHASE3
-
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT00346801 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959 ·Status: COMPLETED ·Phase: PHASE3
-
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
NCT06840782 ·Status: RECRUITING ·Phase: PHASE3
-
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
NCT03141359 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
NCT03064854 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00334815 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
NCT00050830 ·Status: COMPLETED ·Phase: PHASE2